98%
921
2 minutes
20
Osteoporosis is a progressive bone disease characterized by reduced bone density and deterioration of bone microarchitecture, predominantly affecting the elderly population. The ongoing COVID-19 pandemic has introduced additional challenges in osteoporosis management, potentially due to systemic inflammation and direct viral impacts on bone metabolism. This study aims to identify common differentially expressed genes (DEGs) and key molecular pathways shared between osteoporosis and COVID-19, with the goal of uncovering potential therapeutic targets through bioinformatics analysis. Publicly available gene expression datasets GSE164805 (osteoporosis) and GSE230665 (COVID-19) were analyzed to identify overlapping DEGs. Functional enrichment analysis using Gene Ontology (GO), pathway analysis, protein-protein interaction (PPI) network construction, and transcription factor (TF)-hub gene regulatory network analysis were performed to explore the biological significance and regulatory mechanisms of these DEGs. A total of 325 common DEGs were identified between osteoporosis and COVID-19. GO enrichment analysis revealed significant involvement in signal transduction and plasma membrane components. Pathway analysis highlighted the "cytokine-cytokine receptor interaction" pathway as a central player. PPI network analysis identified a module of 193 genes with 397 interactions, from which 10 key hub genes were prioritized: ACTB, CDH1, RPS8, IFNG, RPL17, UBC, RPL36, RPS4Y1, GSK3B, and FGF13. Furthermore, 76 TFs were found to regulate these hub genes, and 15 existing drugs targeting four of these hub genes were identified. This integrative bioinformatics study reveals 15 candidate therapeutic agents that target key regulatory genes shared between osteoporosis and COVID-19, offering promising treatment strategies for osteoporotic patients, especially those impacted by or at risk of SARS-CoV-2 infection.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12413955 | PMC |
http://dx.doi.org/10.1155/ije/8816596 | DOI Listing |
Osteoporos Int
September 2025
University of Alabama at Birmingham, Birmingham, AL, USA.
Unlabelled: Higher area socioeconomic level was associated with a decreased risk of romosozumab discontinuation during COVID-19 lockdown among U.S. Medicare beneficiaries.
View Article and Find Full Text PDFInt J Endocrinol
August 2025
Department of Geriatrics, Zhongshan Hospital Xiamen University, School of Medicine, Xiamen University, Xiamen 361000, Fujian, China.
Osteoporosis is a progressive bone disease characterized by reduced bone density and deterioration of bone microarchitecture, predominantly affecting the elderly population. The ongoing COVID-19 pandemic has introduced additional challenges in osteoporosis management, potentially due to systemic inflammation and direct viral impacts on bone metabolism. This study aims to identify common differentially expressed genes (DEGs) and key molecular pathways shared between osteoporosis and COVID-19, with the goal of uncovering potential therapeutic targets through bioinformatics analysis.
View Article and Find Full Text PDFGlobal Spine J
September 2025
Department of Orthopaedic, Peking University First Hospital, Beijing, China.
Study DesignProspective Cohort Study.ObjectiveTo compare the effectiveness and safety of perioperative denosumab, bisphosphonates, and a control group in promoting lumbar fusion after midline lumbar fusion (MIDLF) surgery in patients with osteopenia or osteoporosis.MethodsThis prospective cohort study enrolled 54 patients with osteopenia or osteoporosis undergoing MIDLF surgery.
View Article and Find Full Text PDFMedicina (Kaunas)
July 2025
Department of Thoracic Medicine, Family Medicine, Geriatric Medicine, Medical Research and Medical Education, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi City 60002, Taiwan.
: COVID-19 may have long-term adverse effects on bone health, particularly in individuals aged ≥50 years with obesity or diabetes, who are predisposed to impaired bone quality. : This retrospective cohort study used TriNetX data from 141 healthcare organizations across North America and Western Europe. Patients aged ≥50 years with overweight (body mass index 25-30 kg/m), obesity (body mass index ≥ 30 kg/m), or type 2 diabetes (T2DM) and COVID-19 (2019-2024) were propensity score-matched to non-COVID-19 controls.
View Article and Find Full Text PDFEndocrine
August 2025
Institute of Endocrine and Metabolic Sciences, Università Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy.
Introduction: In a previous cohort of patients with new-onset of Graves' Disease (GD) during 2021, a "postvaccine early-onset (PoVEO)" after anti-COVID-19 vaccination emerged as a new and frequent nosological entity occurring in approximately one third of patients. Similar cohorts have also been reported with GD after anti-COVID vaccines, but to date there are no available data on long-term clinical outcomes.
Methods: This is a single-center retrospective study evaluating the 24-month clinical course of patients with early-onset (<4 weeks) GD after anti-COVID vaccination (PoVEO) compared to non-PoVEO patients.